Abstracts

Alcohol Induced Severe Pancreatitis Causing Thrombotic Thrombocytopenic Purpura

Introduction:

11/04/2022

TRIATLON - Triple Class Exposed/Refractory Multiple Myeloma Patients: A Real World Analysis (RWA) from the Austrian Myeloma Registry (AMR)

Introduction:Clinical trials are biased towards the younger and fitter. Therefore TRIATLON compared a real-world (RW) population of MM pts. in triple exposed (TE) and/or refractory (TR) s...

Ella E. Willenbacher , MD;

11/04/2022

Double-Hit High-grade Primary Cardiac Lymphoma (PCL) Presenting as Asymptomatic Tachycardia and Breast Masses in an Immunocompetent female

Introduction:High-grade B cell lymphomas are rare, aggressive diffuse Large B cell lymphomas (DBCLs) with genetic translocations involving MYC plus BCL2 and/or BCL6 (double or triple hit)...

Uczkowski Dariusz ;

11/04/2022

Treatment of Eculizumab Refractory Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review about Current Treatment Options and Future Direction

Background:

Saad Syed ;

Reda Khan ;

Fahmida Khurram ;

Danish Safi ;

Faiza Humayun Khan ;

Salah Ud Din Safi ;

11/04/2022

Patient Outcomes In Those Diagnosed With Multiple Myeloma Over A 5-Year Period In India

Introduction:Multiple myeloma (MM) is the second most common hematological malignancy worldwide. The treatment of MM is induction therapy followed by an autologous stem cell transplant (A...

Ahmed Salih ;

Sasmith R. Menakuru ;

Amir F. Beirat ;

Vijaypal Dhillon ;

11/04/2022

Subcutaneous Epcoritamab Combined With R-CHOP for First-Line Treatment of Patients With High-Risk Diffuse Large B-Cell Lymphoma: Phase 1/2 Update

Introduction:

Lorenzo Falchi ;

Kim M. Linton ;

Aqeel Abbas ;

Brian Elliott ;

David Belada ;

Joshua Brody ;

Yasmin Karimi ;

Raul Cordoba ;

Sylvia Snauwaert ;

Jun Wu ;

Liwei Wang ;

Michael Roost Clausen ;

Fritz Offner ;

11/04/2022

End-of-treatment PET in Early-stage Hodgkin lymphoma: Valuable in Addition to Interim-PET

Introduction:Recent clinical trials have demonstrated the prognostic importance of the F18-fluorodeoxyglucose interim-PET scan in early-stage classical Hodgkin lymphoma (HL); however, the...

Bradford Hoppe ;

Patrick B. Johnston ;

Ivana N. Micallef ;

Thomas M. Habermann , MD;

Stephen Ansell ;

Karan Chohan ;

Jason R. Young ;

Scott Lester ;

Muhammad A. Moustafa ;

Allison Rosenthal ;

Han W. Tun ;

11/04/2022

Selinexor for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Introduction:Multiple Myeloma (MM) cells show resistance to standard therapies due to overexpression of the transport protein, Exportin 1. Selinexor is a novel drug that targets the Expor...

Maham Babar ;

Madeeha S. Waleed ;

Arslan Inayat ;

Danish Safi ;

Anum Babar ;

Hina Zubair ;

Mainoma Bano ;

Sana Rafique ;

Arzu Shahid ;

11/04/2022

CIO 2022-1 Transarterial Chemoembolization ± (Tremelimumab and Durvalumab ± Lenvatinib) in Hepatocellular Carcinoma: EMERALD-3

Purpose: Locoregional therapies such as transarterial chemoembolization (TACE) are the most common treatments for patients with intermediate-stage hepatocellular carcinoma (HCC). Although...

10/18/2022

CIO 2022-2 Embolization of Primary and Secondary Renal Cell Carcinoma Tumors with the GPX Embolic Device

Purpose: The GPX Embolic System is a novel embolic agent designed for use in durable and preoperative transcatheter embolization procedures. The GPX Embolic Material is a low-viscosity fl...

Martin Krauss ;

Ryan O'Hara ;

Colin T. Phillips , MD;

J. Jones ;

Andrew Holden , MBChB;

10/18/2022